% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{vanAken:304998,
      author       = {E. S. M. van Aken and B. Devnani and A. Prelaj and L.
                      Castelo-Branco and C. A. M. Marijnen and D. Martins-Branco
                      and M. A. Gambacorta and A. Lamarca and K. Harrington and G.
                      Minniti and M. Hecht and D. Papamichael and M. Krause$^*$
                      and R. Cathomas and K. Lindberg and S. M. O'Cathail and U.
                      Nestle and J. Barriuso and S. Nowicki and C. Rödel$^*$ and
                      P. Boot and C. Belka and U. Ricardi and F. Lordick and D. De
                      Ruysscher and G. Pentheroudakis and M. C. de Jong and A. K.
                      Gandhi},
      title        = {{ESMO}-{ESTRO} consensus statements on the safety of
                      combining radiotherapy with immune checkpoint inhibitors,
                      {VEGF}({R}) inhibitors, or multitargeted tyrosine kinase
                      inhibitors.},
      journal      = {Annals of oncology},
      volume       = {37},
      number       = {1},
      issn         = {0923-7534},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-01989},
      pages        = {17-32},
      year         = {2026},
      note         = {Volume 37, Issue 1, January 2026, Pages 17-32},
      abstract     = {The combination of radiotherapy (RT) with targeted agents
                      or immunotherapy may result in improved outcomes, but it can
                      also increase toxicity. However, there is a paucity of
                      high-quality toxicity data, leading to an absence of
                      evidence-based guidelines.To address this, ESMO and ESTRO
                      initiated a series of systematic reviews followed by a
                      Delphi consensus process to develop multidisciplinary,
                      evidence-based consensus statements regarding the safety of
                      combining RT with such agents. The current publication
                      describes the combination of RT with immune checkpoint
                      inhibitors (ICIs), vascular endothelial growth factor
                      (receptor) (VEGF(R)) inhibitors, or multitargeted tyrosine
                      kinase inhibitors (TKIs). By systematically covering
                      different drug classes and irradiated areas, 76 clinical
                      scenarios were evaluated during two Delphi rounds with 20
                      international experts. Safety statements were developed for
                      each scenario, based on the systematic literature reviews.A
                      total of 5,921 records were screened during the systematic
                      literature review process for ICIs, VEGF(R) inhibitors and
                      multitargeted TKIs, and 159 reports were selected for
                      inclusion in the final literature reviews and the database.
                      During the two Delphi rounds, agreement was reached
                      regarding the safety statements for 74 clinical
                      scenarios.Generally, the expected toxicity of combining RT
                      with ICIs is low, particularly for PD-(L)1 inhibitors. For
                      most combinations with VEGF(R) inhibitors and multitargeted
                      TKIs, exercising caution is recommended. The evidence-based
                      safety statements developed during this comprehensive
                      project, provide practical guidance on combining RT with
                      targeted cancer therapies and immunotherapy.},
      keywords     = {Consensus statements (Other) / Immune checkpoint inhibitors
                      (Other) / Radiotherapy (Other) / Systematic review (Other) /
                      Toxicity (Other) / Tyrosine kinase inhibitors (Other)},
      cin          = {DD01 / FM01},
      ddc          = {610},
      cid          = {I:(DE-He78)DD01-20160331 / I:(DE-He78)FM01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41016600},
      doi          = {10.1016/j.annonc.2025.09.008},
      url          = {https://inrepo02.dkfz.de/record/304998},
}